...
首页> 外文期刊>American Journal of Physiology >Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen.
【24h】

Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen.

机译:由骨髓间充质干细胞的营养活性介导的心力衰竭疗法:非侵入性治疗方案。

获取原文
获取原文并翻译 | 示例

摘要

Heart failure carries a poor prognosis with few treatment options. While myocardial stem cell therapeutic trials have traditionally relied on intracoronary infusion or intramyocardial injection routes, these cell delivery methods are invasive and can introduce harmful scar tissue, arrhythmia, calcification, or microinfarction in the heart. Given that patients with heart failure are at an increased surgical risk, the development of a noninvasive stem cell therapeutic approach is logistically appealing. Taking advantage of the trophic effects of bone marrow mesenchymal stem cells (MSCs) and using a hamster heart failure model, the present study demonstrates a novel noninvasive therapeutic regimen via the direct delivery of MSCs into the skeletal muscle bed. Intramuscularly injected MSCs and MSC-conditioned medium each significantly improved ventricular function 1 mo after MSC administration. MSCs at 4 million cells/animal increased fractional shortening by approximately 40%, enhanced capillary and myocyte nuclear density by approximately 30% and approximately 80%, attenuated apoptosis by approximately 60%, and reduced fibrosis by approximately 50%. Myocyte regeneration was evidenced by an approximately twofold increase in the expression of cell cycle markers (Ki67 and phosphohistone H(3)) and an approximately 13% reduction in mean myocyte diameter. Increased circulating levels of hepatocyte growth factor (HGF), leukemia inhibitory factor, and macrophage colony-stimulating factor were associated with the mobilization of c-Kit-positive, CD31-positive, and CD133-positive progenitor cells and a subsequent increase in myocardial c-Kit-positive cells. Trophic effects of MSCs further activated the expression of HGF, IGF-II, and VEGF in the myocardium. The work highlights a cardiac repair mechanism mediated by trophic cross-talks among the injected MSCs, bone marrow, and heart that can be explored for noninvasive stem cell therapy.
机译:心力衰竭与少数治疗方案进行预后差。虽然心肌干细胞治疗试验传统上依赖于颅内输注或肌内注射途径,但这些细胞递送方法是侵入性的,并且可以在心脏中引入有害的瘢痕组织,心律失常,钙化或微观程度。鉴于心力衰竭的患者处于增加的手术风险,非侵入性干细胞治疗方法的发展是逻辑上的吸引力。利用骨髓间充质干细胞(MSCs)和使用仓鼠心力衰竭模型的营养效果,本研究通过将MSCs直接递送到骨骼肌床中的新型非侵入性治疗方案。肌内注射的MSC和MSC条件培养基每种显着改善的室内功能1MO在MSC给药后。 MSCs在400万个细胞/动物中增加了大约40%,增强毛细胞和肌细胞核密度的分数缩短约30%,约80%,减去凋亡约为60%,减少约50%。通过细胞循环标记物(Ki67和磷酸孔H(3))表达的大致两倍增加,证明了肌细胞再生,其平均肌细胞直径约为13%。增加肝细胞生长因子(HGF),白血病抑制因子和巨噬细胞菌落刺激因子的循环水平与动员C-kit阳性,CD31阳性和CD133阳性祖细胞和随后的心肌C增加有关-Kit-阳性细胞。 MSCs的营养效果进一步活化了心肌中HGF,IGF-II和VEGF的表达。该工作突出了通过探索无创干细胞疗法的注射的MSCs,骨髓和心脏中营养串扰介导的心脏修复机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号